Article
Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials.
ESMO open - 1 Feb 2022
Szeto C W, Kurzrock R, Kato S, Goloubev A, Veerapaneni S, Preble A, Reddy S K, Adashek J J
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitors (ICIs) and genomic biomarker-driven targeted therapies have revolutionized the modern oncologic treatment arsenal. The next step has been to combine targeted agents and ICIs. In doing so, some combination regimens may be more logical than others. PATIENTS AND METHODS: Whole-exome and whole-transcriptome sequencing were performed on 2739 unselected later-stage clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.